CN108913764A - Detect the method and application of ALOX15 gene expression amount in nasal cavity cast-off cells - Google Patents
Detect the method and application of ALOX15 gene expression amount in nasal cavity cast-off cells Download PDFInfo
- Publication number
- CN108913764A CN108913764A CN201810720285.4A CN201810720285A CN108913764A CN 108913764 A CN108913764 A CN 108913764A CN 201810720285 A CN201810720285 A CN 201810720285A CN 108913764 A CN108913764 A CN 108913764A
- Authority
- CN
- China
- Prior art keywords
- rna
- nasal cavity
- alox15
- cells
- cavity cast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003928 nasal cavity Anatomy 0.000 title claims abstract description 111
- 238000000034 method Methods 0.000 title claims abstract description 101
- 101150054329 ALOX15 gene Proteins 0.000 title claims abstract description 94
- 230000014509 gene expression Effects 0.000 title claims abstract description 77
- 238000006243 chemical reaction Methods 0.000 claims abstract description 68
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 59
- 238000001514 detection method Methods 0.000 claims abstract description 42
- 238000010839 reverse transcription Methods 0.000 claims abstract description 38
- 238000003753 real-time PCR Methods 0.000 claims abstract description 31
- 239000002299 complementary DNA Substances 0.000 claims abstract description 30
- 210000002966 serum Anatomy 0.000 claims abstract description 14
- 230000003321 amplification Effects 0.000 claims abstract description 13
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 238000012360 testing method Methods 0.000 claims abstract description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 217
- 238000000746 purification Methods 0.000 claims description 79
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 68
- 239000000706 filtrate Substances 0.000 claims description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- 239000000872 buffer Substances 0.000 claims description 44
- 101001064853 Homo sapiens Polyunsaturated fatty acid lipoxygenase ALOX15 Proteins 0.000 claims description 42
- 102100031950 Polyunsaturated fatty acid lipoxygenase ALOX15 Human genes 0.000 claims description 42
- 230000001376 precipitating effect Effects 0.000 claims description 39
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims description 38
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 38
- 239000006228 supernatant Substances 0.000 claims description 37
- 239000012153 distilled water Substances 0.000 claims description 34
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 30
- 238000002156 mixing Methods 0.000 claims description 27
- 235000019441 ethanol Nutrition 0.000 claims description 24
- 238000005259 measurement Methods 0.000 claims description 24
- 238000011144 upstream manufacturing Methods 0.000 claims description 24
- 238000012408 PCR amplification Methods 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 22
- 208000000592 Nasal Polyps Diseases 0.000 claims description 18
- 108091092562 ribozyme Proteins 0.000 claims description 18
- 230000002255 enzymatic effect Effects 0.000 claims description 17
- 238000006911 enzymatic reaction Methods 0.000 claims description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
- 238000013459 approach Methods 0.000 claims description 16
- 208000016366 nasal cavity polyp Diseases 0.000 claims description 16
- 238000000197 pyrolysis Methods 0.000 claims description 16
- 238000001179 sorption measurement Methods 0.000 claims description 16
- 238000005498 polishing Methods 0.000 claims description 14
- 238000012545 processing Methods 0.000 claims description 14
- 238000000137 annealing Methods 0.000 claims description 11
- 238000005119 centrifugation Methods 0.000 claims description 11
- 230000001684 chronic effect Effects 0.000 claims description 11
- 230000004087 circulation Effects 0.000 claims description 11
- 238000004925 denaturation Methods 0.000 claims description 10
- 230000036425 denaturation Effects 0.000 claims description 10
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 9
- 102100034343 Integrase Human genes 0.000 claims description 8
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 8
- 230000002779 inactivation Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000006166 lysate Substances 0.000 claims description 7
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000005725 8-Hydroxyquinoline Substances 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 229960003540 oxyquinoline Drugs 0.000 claims description 3
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 3
- 230000002035 prolonged effect Effects 0.000 claims 1
- 239000000090 biomarker Substances 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 103
- 108020004414 DNA Proteins 0.000 description 57
- 208000037062 Polyps Diseases 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 239000013641 positive control Substances 0.000 description 13
- 239000013642 negative control Substances 0.000 description 12
- 238000004321 preservation Methods 0.000 description 12
- 210000001331 nose Anatomy 0.000 description 10
- 210000003979 eosinophil Anatomy 0.000 description 9
- 230000001575 pathological effect Effects 0.000 description 9
- 230000009514 concussion Effects 0.000 description 8
- 238000011010 flushing procedure Methods 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000003416 augmentation Effects 0.000 description 6
- 210000000222 eosinocyte Anatomy 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 238000002247 constant time method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Substances OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- -1 linoleic acid Olefin Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- ZIOZYRSDNLNNNJ-LQWMCKPYSA-N 12(S)-HPETE Chemical compound CCCCC\C=C/C[C@H](OO)\C=C\C=C/C\C=C/CCCC(O)=O ZIOZYRSDNLNNNJ-LQWMCKPYSA-N 0.000 description 1
- BFWYTORDSFIVKP-USWFWKISSA-N 15-HPETE Chemical compound CCCCCC(OO)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O BFWYTORDSFIVKP-USWFWKISSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229930184725 Lipoxin Natural products 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- XAXHEVRKPSEDKX-UHFFFAOYSA-N cyanic acid;guanidine Chemical compound [O-]C#N.NC([NH3+])=N XAXHEVRKPSEDKX-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000002639 lipoxins Chemical class 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000011309 nasal bleeding Diseases 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 201000005936 periventricular leukomalacia Diseases 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention proposes a kind of method and application for detecting the non-diagnostic purpose of ALOX15 gene expression amount in nasal cavity cast-off cells, includes the following steps:RNA is extracted from nasal cavity cast-off cells, it is cDNA by total serum IgE reverse transcription, the specific primer of ALOX15 gene and reference gene specific primer and reference gene that ALOX15 gene is respectively adopted in cDNA is carried out by real-time fluorescence quantitative PCR amplification using quantitative polyase chain reaction, testing result based on amplified production calculates ALOX15 gene expression amount.The method of the present invention, using the ALOX15 gene of Effective selection as biomarker, detection method to its gene expression amount is provided, realize the calculating to ALOX15 gene expression amount in nasal cavity cast-off cells, ALOX15 gene expression amount can be effectively obtained, and the method provided is simple and fast, sensibility is high, it is reproducible, it is suitable for wide popularization and application.
Description
Technical field
The invention belongs to ALOX15 gene tables in biomedicine technical field more particularly to a kind of detection nasal cavity cast-off cells
Up to the method for amount.
Background technique
Chronic nasosinusitis is with nasal polyp (Chronic rhinosinusitis with nasal polyps, CRSwNP)
The chronic inflammation of sinus mucosa, the visible nasal cavity of physical examination or middle nasal meatus polyp are formed.CRSwNP common sympton is stifled nose, runny nose or nose
Tears refluence, hyposphresia, the bored swollen sense of face or feeling of stress, duration are more than 12 weeks.Illness rate is about 0.5-4%, CRSwNP
It is often accompanied by asthma and allergic rhinitis, has been reported that 7% asthmatic patient suffers from CRSwNP, and the CRSwNP of 26-48% is with heavy breathing
Asthma.CRSwNP pathogenesis is also uncertain at present, and mucosal epithelial cells destroy, host immune system is unbalance and pathogenic microorganism enters
Invade the main reason for may be its morbidity.The main therapeutic modality of CRSwNP is operation and drug therapy.But studies have shown that even if
By the drug or operative treatment of specification, chronic nasosinusitis is still up to 56% with the recurrence rate of nasal polyp, and it is raw to seriously affect patient
Bioplasm amount, while bringing high medical to pay, but clinical shortage radical treatment method, thus become nasology research field
Emphasis.
Degree according to eosinophils can divide CRSwNP for eosinophil type (Eosinophilic
CRSwNP, ECRSwNP) and Non eosinophilic granulocyte type (Noneosinophilic CRSwNP, nonECRSwNP), the two is faced
Bed performance, medication and prognosis are different, and the clinical symptoms of eosinophil type are heavier, with nose is stifled and hyposphresia based on, it is more
It is associated with asthma, Postoperative recurrent rate is higher.Eosinophils degree and relapse are the closest in human nasal polyps tissues,
When the cell percentages are more than 27% in tissue, risk of recurrence is more than 90%.Eosinophil type polyp is to sugared cortical hormone
The susceptibility of plain class drug is significantly higher than Non eosinophilic granulocyte type.Non eosinophilic granulocyte type clinical symptoms are generally relatively light, and
The probability for merging asthma is smaller, and airway inflammation is lighter, and Postoperative recurrent rate is low compared with eosinophil type, to macrolides medicine
Object therapeutic response is good.Western countries are mainly shown as TH2 inflammatory reaction based on eosinophil type, and the acidophilus in China
Property granulocyte type and Non eosinophilic granulocyte type ratio account for about half, and Non eosinophilic granulocyte type is mainly shown as TH1/TH17
Based on inflammatory reaction.In conclusion eosinophil type and Non eosinophilic granulocyte type are in immunopathogenesis type, clinical condition
There are significantly different for shape, drug therapy reaction and prognosis.Different chronic nasosinusitis treat plan with inflammation/pathological of nasal polyp
It is slightly different.So the identification to chronic nasosinusitis with the pathological of nasal polyp is particularly important.
The judgement of two kinds of hypotypes is lacked non-invasive mainly according to histopathology specimen staining after bronchia mucosal biopsy at present
Biological markers are used for antidiastole.After patient obtains polyp sample under nasal endoscopes, the Pathologic specimens such as progress paraffin is fixed
Conventional treatment, then carry out haematoxylin Yihong dyeing, followed by the inflammatory cell of ultramicroscopic observation tissue infiltration
(main inflammatory cell includes eosinophil, neutrophil leucocyte, lymphocyte, thick liquid cell) infiltrates number, carries out cell point
Type.The shortcomings that bronchia mucosal pathological biopsy, is as follows:1. being invasive inspection:The infection risk for increasing patient is not suitable for being immunized
Power lower crowd such as children, the elderly etc.;Nasal bleeding when materials often causes patient frightened and worry.2. being difficult to obtain disease
The real-time dynamic-change information of disease:Pathological biopsy cannot be carried out to healing stage mucous membrane after surgery.But clinical data shows chronic nose
Sinusitis can be lapsed to the pathological classification of nasal polyp with drug therapy, operative treatment etc., can not with the pathological biopsy result before treatment
Represent the feature of whole disease durations.3. time-consuming and increase medical treatment cost, general to pathological examination is obtained from tissue samples are obtained
3-4 working day.Due to can not obtain the same day or next day as a result, the additional transportation expenses of generations such as nonlocal patient sees a doctor, hotel expense,
Registration fee increases medical treatment cost.4. the inflammatory cell quantity that different pathologists counts has can there are certain human error
Can be different, influence the judgement of polyp parting.5. tissue pathological slice relatively limits to, it can only reflect the sample inflammation shape of slice position
State cannot reflect the overall picture of tissue, be likely to result in mistaken diagnosis.6. every piece requires Pathologis artificial counting, it is difficult to
Batch operation.
In recent years the real-time fluorescence quantitative PCR risen compensates for the deficiency of above-mentioned technology.This method is in PCR reaction system
Fluorophor is added, using the entire PCR process of the accumulation real-time monitoring of fluorescence signal, finally according to fluorescence signal to surveyed DNA
Sample carries out quantitative analysis, and this method is easy to operate, and sensibility is high, and reproducible and result accuracy is high.However the prior art
In not yet disclose effectively provide detection nasal cavity cast-off cells in ALOX15 gene expression amount method, preferably to get nasal cavity
ALOX15 gene content situation in cast-off cells.
Summary of the invention
The present invention for the above technical issues, proposes ALOX15 gene expression amount in a kind of detection nasal cavity cast-off cells
Method.
In order to achieve the above object, the technical solution adopted by the present invention is:
A method of ALOX15 gene expression amount in detection nasal cavity cast-off cells includes the following steps:It falls off from nasal cavity
RNA is extracted in cell, by total serum IgE reverse transcription be cDNA, using quantitative polyase chain reaction by cDNA ALOX15 gene and
The specific primer of ALOX15 gene is respectively adopted in reference gene specific primer and reference gene carries out real time fluorescent quantitative
PCR amplification, the testing result based on amplified production calculate ALOX15 gene expression amount.
Preferably, the upstream primer of ALOX15 gene such as SEQIDNO:Shown in 2, the downstream primer of ALOX15 gene is such as
SEQIDNO:Shown in 3.
Preferably, the reference gene is GAPDH, the upstream primer of the reference gene such as SEQIDNO:Shown in 4, institute
State downstream primer such as SEQIDNO:Shown in 5.
Preferably, the nasal cavity cast-off cells are obtained using hairbrush in nasal polyp surface, and it will acquire nasal cavity and fall off carefully
Hairbrush after born of the same parents is placed in cell pyrolysis liquid to be saved in 4 DEG C or less.
Preferably, the method for extracting RNA from nasal cavity cast-off cells, including two methods, wherein first method packet
Include following steps:
Step 1:The nasal cavity cast-off cells are dissolved in 100~2000 μ L cell pyrolysis liquids, and are added in equal volume
Ethyl alcohol is added after mixing into RNA purification column, after centrifugal treating, removes the filtrate in collecting pipe, the RNA is purified
Column is placed in collecting pipe;
Step 2:The first buffer of 300 μ of μ L~700 L is added into the RNA purification column obtained in step 1, is centrifuged
After processing, the first filtrate is removed;Continue that 400 μ of μ L~800 the second buffers of L are added to the RNA purification column, after centrifugal treating,
The second filtrate is removed, takes RNA purification column through affording RNA.
Preferably, the method for extracting RNA from nasal cavity cast-off cells, further comprising the steps of:To described in removing
10~100 μ L DNA enzymatic reaction solutions are added in RNA purification column after second filtrate, and after stewing process, 300 μ of μ L~700 are added
Second buffer described in L after centrifugal treating, removes third filtrate, takes RNA purification column after eluting using spectrophotometer measurement
RNA purity, obtains RNA;
The preparation method of the DNA enzymatic reaction solution includes the following steps:DNA enzymatic buffer, recombinant dnase are taken, RNA enzyme is gone
Distilled water be mixed to get DNA enzymatic reaction solution.It is preferred that the preparation method of the DNA enzymatic reaction solution includes the following steps:Take 5 μ L
10 × DNA enzymatic buffer, 4 μ L recombinant dnases, 41 μ L go the distilled water of RNA enzyme to be mixed to get DNA enzymatic reaction solution.
Preferably, genome content is lower or when material initial amount is less when carrying out RNA extraction, it is described de- from nasal cavity
The method for extracting RNA is fallen in cell, it is further comprising the steps of:In the step 1, the nasal cavity cast-off cells are dissolved in cell and split
It is first added after in solution liquid into genomic DNA adsorption column and takes filtrate, then isometric ethyl alcohol is added into the filtrate.
Preferably, in order to obtain the RNA of higher concentration, the method that RNA is extracted from nasal cavity cast-off cells is also wrapped
Include following steps:Take RNA purification column to be eluted that the distilled water for removing RNA hydrolase or pyrocarbonic acid diethyl ester processing water, room is added
After temperature is stood, RNA is obtained using spectrophotometer measurement RNA purity through centrifugal treating, the elution RNA purification column.
Wherein step 1 can be crushed rapidly nasal cavity cast-off cells using cell pyrolysis liquid and nasal cavity cast-off cells is inhibited to discharge
The substance of nuclease out;Using genomic DNA adsorption column for removing genomic DNA;RNA purification column in step 2 is used for
It is enriched with RNA;Wherein collecting pipe be used for collects remove genomic DNA after solution, for remove be adsorbed with RNA purification column it is miscellaneous
First buffer of matter, the second buffer for removing impurity and salinity in RNA solution.
Specifically, the first method for extracting RNA from nasal cavity cast-off cells, includes the following steps:
Step 1:The nasal cavity cast-off cells are dissolved in 300 μ L cell pyrolysis liquids, and 70% isometric second is added
Solution is uniformly mixed by alcohol using liquid-transfering gun;Mixed liquor is added into RNA purification column immediately, 12000 revs/min, is centrifuged
1min removes filtrate, the RNA purification column is placed in 2mL collecting pipe;
Step 2:It is added the first buffer of 500 μ L into the RNA purification column obtained in step 1,12000 revs/min
Clock is centrifuged 30s, removes the first filtrate;Continue that 600 the second buffers of μ L are added to the RNA purification column, 12000 revs/min,
It is centrifuged 30s, removes the second filtrate;
Step 3:5 μ 10 × DNA enzymatic of L buffers, 4 μ L recombinant dnases are taken, 41 μ L go the distilled water of RNA enzyme through mixing
To DNA enzymatic reaction solution, 50 μ L DNA enzymatic reaction solutions are added into the RNA purification column after removing second filtrate, are stored at room temperature
15 minutes, the second buffer described in 350 μ L is added, 12000 revs/min, is centrifuged 30s, removes third filtrate;
Step 4:The RNA purification column that third filtrate is removed in step 3 is placed in 1.5mL without RNA hydrolase collecting pipe, to
The distilled water for removing RNA hydrolase of 50 μ L is added in RNA purification column or 0.1% pyrocarbonic acid diethyl ester handles water, is stored at room temperature 5 points
Clock, is centrifuged 2min, eluted rna purification column, using the OD260/OD280 of spectrophotometer measurement RNA solution by 12000 revs/min
When ratio is 1.7~2.1, RNA is obtained.
Or the method that RNA is extracted from nasal cavity cast-off cells, include the following steps:
Step 1:Genomic DNA adsorption column is taken to be placed in 2mL collecting pipe, the nasal cavity cast-off cells are dissolved in 100~
It is added after in 2000 μ L cell pyrolysis liquids into genomic DNA adsorption column, takes filtrate, isometric 70% is added into the filter
Ethyl alcohol is added after mixing into RNA purification column, 12000 revs/min, is centrifuged 1min, is removed filtrate, the RNA is purified
Column is placed in 2mL collecting pipe;
Step 2:It is added the first buffer of 500 μ L into the RNA purification column obtained in step 1,12000 revs/min
Clock is centrifuged 30s, removes the first filtrate;Continue that 600 the second buffers of μ L are added to the RNA purification column, 12000 revs/min,
It is centrifuged 30s, removes the second filtrate;
Step 3:The RNA purification column that the second filtrate is removed in step 2 is placed in 1.5mL without RNA hydrolase collecting pipe, to
The distilled water for removing RNA hydrolase of 50 μ L is added in RNA purification column or 0.1% pyrocarbonic acid diethyl ester handles water, is stored at room temperature 5 points
Clock, is centrifuged 2min, eluted rna purification column, using the OD260/OD280 of spectrophotometer measurement RNA solution by 12000 revs/min
When ratio is 1.7~2.1, RNA is obtained.
Preferably, the second method for extracting RNA from nasal cavity cast-off cells, includes the following steps:To being equipped with
Be added in the centrifuge tube of nasal cavity cast-off cells 0.1mL~20mL RNA extract dissolved, vibrate after RNA extracting is added
0.1~0.5 times of chloroform of liquid product, concussion mix, are stored at room temperature, the centrifuge tube is centrifuged, and take supernatant, described in addition
0.5~3 times of isopropanol of chloroform volume stands after mixing, is centrifuged, abandons supernatant, retains the first precipitating, to first precipitating
The ethyl alcohol of middle 0.5~5 times of the concentration 65%~90% that the isopropanol volume is added mixes, centrifugation after washed, in abandoning
Clearly, retain the second precipitating;The centrifuge tube is covered tightly, is centrifuged again, supernatant is removed, continues to be added 0.01 into the centrifuge tube
~5mL goes RNA enzyme and the water of DNA enzymatic is gone to dissolve second precipitating, using spectrophotometer measurement RNA purity, obtains RNA.
Preferably, the RNA extract is Trizol, RNAiso Blood, RNAiso Plus or other contain benzene
The reagent of any one or more of phenol, guanidinium isothiocyanate, 8-hydroxyquinoline, guanidinium isothiocyanate and beta -mercaptoethanol.
Preferably, the second method for extracting RNA from nasal cavity cast-off cells, includes the following steps:To being equipped with
After addition 0.1~20mLRNA extract is dissolved, vibrated in the centrifuge tube of nasal cavity cast-off cells, it is stored at room temperature 3~7min;
40 μ L~5mL chloroforms are added, concussion mixes, and is stored at room temperature 3~7min, and in 3 DEG C~5 DEG C, 10000~14000r/min is centrifuged 10
~20min;40 μ L~8mL of supernatant is taken, isometric isopropanol is added, 8~12min is stood after mixing, in 3 DEG C~5 DEG C,
10000~14000r/min is centrifuged 10~20min and abandons supernatant, retains the first precipitating;Addition and isopropyl into first precipitating
The ethyl alcohol of the isometric concentration 65%~90% of alcohol, on 3 DEG C~5 DEG C, 7000~14000r/min, 10~20min of centrifugation, abandoning
Clearly, retain the second precipitating;The centrifuge tube is covered tightly, on 3 DEG C~5 DEG C, 7000~14000r/min, 1~3min of centrifugation, removing
Clear liquid, stand 10~20min after continue into the centrifuge tube be added 0.01~5mL go RNA enzyme and go DNA enzymatic water dissolve institute
The second precipitating is stated, using spectrophotometer measurement RNA purity, obtains RNA.
Specifically, the second method for extracting RNA from nasal cavity cast-off cells, includes the following steps:To equipped with nose
After addition 1mLRNA extract is dissolved, vibrated in the centrifuge tube of chamber cast-off cells, it is stored at room temperature 5min;200 μ L chlorine are added
Imitative, concussion mixes, and is stored at room temperature 5min, and in 4 DEG C, 12000r/min is centrifuged 15min;200 μ L of supernatant is taken, it is different that 200 μ L are added
Propyl alcohol stands 10min after mixing, and in 4 DEG C, 12000r/min is centrifuged 15min and abandons supernatant, retains the first precipitating;To described first
The ethyl alcohol with the isometric concentration 75% of isopropanol is added in precipitating, in 4 DEG C, 7500r/min is centrifuged 15min, abandons supernatant, retains
Second precipitating;Cover tightly the centrifuge tube, in 4 DEG C, 7500r/min is centrifuged 2min, removes supernatant, stand continue after 15min to
50 μ L are added in the centrifuge tube to go RNA enzyme and the water of DNA enzymatic is gone to dissolve second precipitating, using spectrophotometer measurement
RNA solution OD260/OD280 ratio is 1.7~2.1, obtains RNA.
Preferably, the method that total serum IgE reverse transcription is cDNA is included the following steps:The reverse transcription of 1~3 μ L is taken to mix
Liquid, 0~10 μ L go RNA hydrolase distilled water and the RNA of extraction to issue raw reverse transcription reaction 15min in 37 DEG C of temperature conditions,
The inactivation reaction for issuing raw reverse transcriptase in 84 DEG C of temperature conditions afterwards, obtains reverse transcription product cDNA.
More preferably, the method that total serum IgE reverse transcription is cDNA is included the following steps:Take the reverse transcription of 2 μ L
Mixed liquor, the described of 8 μ L go RNA hydrolase distilled water and total amount to be no more than the total serum IgE of 500ng or volume no more than 8 μ L,
It is described to go RNA hydrolase distilled water polishing to 10 μ L;Reverse transcription reaction is carried out after soft mixing, condition is as follows:In 37 DEG C of item
Under part, 15 minutes reverse transcription reactions are carried out;Under conditions of 85 DEG C, the inactivation reaction of 5 seconds reverse transcriptase is carried out;Product 4
DEG C place.Wherein reaction system can accordingly amplify on demand, 10 μ L reaction systems can the maximum total serum IgE for using 500ng, this field
Technical staff can select according to actual needs.
Preferably, the real-time fluorescence quantitative PCR amplification includes the following steps:
Step 1:Prepare real-time fluorescence quantitative PCR reaction solution:PCR premix including 1 μ of μ L~25 L, 0 μ of μ L~10 L
Distilled water polishing total volume water to 10 μ L, 0 μ of μ L~2 L machine fluorescence compensation and corrigent, 0.01~100 μM
The upstream primer of ALOX15 gene, the downstream primer of 0.01~100 μM of ALOX15 gene, 0.01~100 μM of reference gene
Upstream primer, the downstream primer of 0.01~100 μM of reference gene, the cDNA of 0.01 μ of μ L~5 L;
Step 2:It is fixed that real-time fluorescence is carried out using two-step method PCR amplification standardization program or three-step approach PCR amplification standardization program
Measure PCR detection;
Step 3:Calculate ALOX15 gene expression amount.
More preferably, real-time fluorescence quantitative PCR reaction solution is prepared:PCR premix including 5 μ L, 2.8 μ L's is double
Steam machine fluorescence compensation and corrigent of the water polishing total volume water to 10 μ L, 0.2 μ L, the upstream of the ALOX15 gene of 0.5 μ L
Primer, the downstream primer of the ALOX15 gene of 0.5 μ L, the upstream primer of the reference gene of 0.5 μ L, the reference gene of 0.5 μ L
The RNA of downstream primer, the cDNA of 1ng/ μ L or 0.01 μ L to 5 μ L.
Preferably, the reaction condition of the two-step method PCR amplification standardization program includes the following steps:1st stage:95
Initial denaturation 30 seconds under conditions of DEG C;The reaction of 2nd stage PCR:Under conditions of 95 DEG C, reaction 15 seconds, under conditions of 60 DEG C, instead
It answers 60 seconds, annealing extends, and so carries out 40 circulations;
The reaction condition of the three-step approach PCR amplification standardization program includes the following steps:1st stage:In 95 DEG C of condition
Lower initial denaturation 2 minutes;The reaction of 2nd stage PCR:It under conditions of 95 DEG C, reacts 1 minute, under conditions of 55 DEG C, reacts 1 point
Clock reacts 1 minute under conditions of 72 DEG C, so carries out 40 circulations;Last 72 DEG C, annealing in 7 minutes extends;
The method for calculating the ALOX15 gene expression amount is:Calculate Δ CT or 2-ΔΔCTTo calculate the expression of target gene
Amount;Wherein Δ CT=(CT (ALOX15)-CT (GAPDH)) ,-Δ Δ CT=- (Δ CT (processing sample CT (ALOX15)-CT
(GAPDH))-healthy control group average delta CT);The each control group Δ CT of healthy control group average delta CT=∑ (CT (ALOX15)-
CT (GAPDH))/control group sample number.
The method of ALOX15 gene expression amount is in preparation for detecting with nose in a kind of above-mentioned detection nasal cavity cast-off cells
Application in the kit of the chronic nasosinusitis hypotype of polyp.
Compared with prior art, the advantages and positive effects of the present invention are:
1, the method provided by the invention for detecting ALOX15 gene expression amount in nasal cavity cast-off cells, with Effective selection
ALOX15 gene provides the detection method to its gene expression amount as biomarker, realizes in nasal cavity cast-off cells
The calculating of ALOX15 gene expression amount can effectively obtain ALOX15 gene expression amount, and the method provided is simple and fast, sensibility
Height, it is reproducible, it is suitable for wide popularization and application.
2, in detection nasal cavity cast-off cells provided by the invention ALOX15 gene expression amount method, wherein ALOX15 gene
Lipoxygenase protein can be encoded, the enzyme effect of coding is in various polyunsaturated fatty acid substrates to generate various bioactive lipids
Matter medium, such as eicosanoid, heparin, lipoxin etc..By arachidonic acid be converted into 12- hydroperoxidation eicosatetraenoic acid/
12-HPETE and 15- hydroperoxidation eicosatetraenoic acid/15-HPETE.It is also 18 carbon two of 13- hydrogen peroxide by linoleic acid
Olefin(e) acid.21 carbon tetraenoic acid of (12S)-hydrogen peroxide/(12S)-HPETE can also be acted on to generate liver mycin A3.Coding
Enzyme and its reaction product can adjust inflammation and immune response, disease relevant to ALOX15 includes periventricular leukomalacia
Deng.Its apoptotic cell during removing inflammation by the phosphatidyl-ethanolamine help that film in oxidation macrophage combines, and press down
System autoimmune response relevant to inflammatory mononuclear cells removing apoptotic cell.ALOX15 is not yet disclosed in currently available technology
Gene does not find the purposes of the gene.What wherein invention provided is directed to ALOX15 gene expression amount in nasal cavity cast-off cells
Method can be used for detecting ALOX15 expression in nasal cavity cast-off cells, can be used for being further nasal cavity with the chronic of nasal polyp
The detection genescreen technology of nasosinusitis hypotype provides the foundation, and provides reliable basis for clinical guidance and drug therapy.
It ensure that for detecting the kit with the chronic nasosinusitis hypotype of nasal polyp in the feasibility of clinical application.
3, the method provided by the invention for detecting ALOX15 gene expression amount in nasal cavity cast-off cells, is adopted according to actual needs
With Δ Ct or 2-ΔΔCtThe relative quantification method of method has selected the relative constant reference gene of expression quantity, with the quantity of reference gene into
Row standardization, by measuring the different calculating destination gene expression amount of Ct value difference of sample target gene and reference gene, method is easy
Quickly, detection accuracy is high, can reduce testing cost, saves detection time.As a result the advantages that being convenient for interpretation.Greatly improve experiment
Efficiency.
Specific embodiment
The technical scheme in the embodiments of the invention will be clearly and completely described below, it is clear that described implementation
Example is only a part of the embodiment of the present invention, instead of all the embodiments.Based on the embodiments of the present invention, this field is common
Technical staff's every other embodiment obtained without making creative work belongs to the model that the present invention protects
It encloses.
The embodiment of the invention provides a kind of methods of ALOX15 gene expression amount in detection nasal cavity cast-off cells, including with
Lower step:RNA is extracted from nasal cavity cast-off cells, is cDNA by total serum IgE reverse transcription, using quantitative polyase chain reaction by cDNA
In ALOX15 gene and reference gene the specific primer of ALOX15 gene and the specific primer of reference gene is respectively adopted
Real-time fluorescence quantitative PCR amplification is carried out, the testing result based on amplified production calculates ALOX15 gene expression amount.
The present invention screens to obtain by proteomics and transcription group method through a large amount of creative experiments passes through calculating
ALOX15 gene expression amount detects the chronic nasosinusitis hypotype with nasal polyp, and what is provided be directed to ALOX15 gene expression amount
Calculation method it is easy reliable, accuracy is high.Corresponding any report is not yet provided in current existing technology.Wherein it is directed to
ALOX15 gene is known, gene I/D 246, DNA sequence dna such as SEQIDNO:Shown in 1, gene NM is 001140.4.
In an alternative embodiment, the upstream primer of ALOX15 gene such as SEQIDNO:Shown in 2, the downstream of ALOX15 gene
Primer such as SEQIDNO:Shown in 3.For the design of the upstream primer and downstream primer of ALOX15 gene, sensibility is higher, into
When row detection ALOX15 gene expression amount, keep result more acurrate, repeatability is more preferable.
In an alternative embodiment, the reference gene is GAPDH, the upstream primer of the reference gene such as SEQIDNO:
Shown in 4, the downstream primer such as SEQIDNO:Shown in 5.Design of feature at this, in conjunction with the upstream of above-mentioned ALOX15 gene
The downstream primer of primer and ALOX15 gene obtains suitable Δ CT value, to carry out ALOX15 gene expression amount calculating, and has
Higher accuracy rate.
In an alternative embodiment, the nasal cavity cast-off cells are obtained using hairbrush in nasal polyp surface, and will acquire nose
Hairbrush after chamber cast-off cells is placed in cell pyrolysis liquid to be saved in 4 DEG C or less.Method of the invention is based on this kind of mode and avoids
The surface of a wound is caused to patient, improves the safety of patient's inspection, and operate it is more convenient, saved human cost and see a doctor at
This.
In an alternative embodiment, the method that RNA is extracted from nasal cavity cast-off cells, including two methods, wherein first
Kind method includes the following steps:
Step 1:The nasal cavity cast-off cells are dissolved in 100~2000 μ L cell pyrolysis liquids, and are added in equal volume
Ethyl alcohol is added after mixing into RNA purification column, after centrifugal treating, removes the filtrate in collecting pipe, the RNA is purified
Column is placed in collecting pipe;
Step 2:The first buffer of 300 μ of μ L~700 L is added into the RNA purification column obtained in step 1, is centrifuged
After processing, the first filtrate is removed;Continue that 400 μ of μ L~800 the second buffers of L are added to the RNA purification column, after centrifugal treating,
The second filtrate is removed, takes RNA purification column through affording RNA.
Preferably, the method for extracting RNA from nasal cavity cast-off cells, further comprising the steps of:To described in removing
10~100 μ L DNA enzymatic reaction solutions are added in RNA purification column after second filtrate, and after stewing process, 300 μ of μ L~700 are added
Second buffer described in L after centrifugal treating, removes third filtrate, takes RNA purification column after eluting using spectrophotometer measurement
RNA purity, obtains RNA;
The preparation method of the DNA enzymatic reaction solution includes the following steps:DNA enzymatic buffer, recombinant dnase are taken, RNA enzyme is gone
Distilled water be mixed to get DNA enzymatic reaction solution.It is preferred that the preparation method of the DNA enzymatic reaction solution includes the following steps:Take 5 μ L
10 × DNA enzymatic buffer, 4 μ L recombinant dnases, 41 μ L go the distilled water of RNA enzyme to be mixed to get DNA enzymatic reaction solution.
Preferably, genome content is lower or when material initial amount is less when carrying out RNA extraction, it is described de- from nasal cavity
The method for extracting RNA is fallen in cell, it is further comprising the steps of:In the step 1, the nasal cavity cast-off cells are dissolved in cell and split
It is first added after in solution liquid into genomic DNA adsorption column and takes filtrate, then isometric ethyl alcohol is added into the filtrate.
Preferably, in order to obtain the RNA of higher concentration, the method that RNA is extracted from nasal cavity cast-off cells is also wrapped
Include following steps:Take RNA purification column to be eluted that the distilled water for removing RNA hydrolase or pyrocarbonic acid diethyl ester processing water, room is added
After temperature is stood, RNA is obtained using spectrophotometer measurement RNA purity through centrifugal treating, the elution RNA purification column.
Wherein step 1 can be crushed rapidly nasal cavity cast-off cells using cell pyrolysis liquid and nasal cavity cast-off cells is inhibited to discharge
The substance of nuclease out;Using genomic DNA adsorption column for removing genomic DNA;RNA purification column in step 2 is used for
It is enriched with RNA;Wherein collecting pipe be used for collects remove genomic DNA after solution, for remove be adsorbed with RNA purification column it is miscellaneous
First buffer of matter, the second buffer for removing impurity and salinity in RNA solution.
Specifically, the first method for extracting RNA from nasal cavity cast-off cells, includes the following steps:
Step 1:The nasal cavity cast-off cells are dissolved in 300 μ L cell pyrolysis liquids, and 70% isometric second is added
Solution is uniformly mixed by alcohol using liquid-transfering gun;Mixed liquor is added into RNA purification column immediately, 12000 revs/min, is centrifuged
1min removes filtrate, the RNA purification column is placed in 2mL collecting pipe;
Step 2:It is added the first buffer of 500 μ L into the RNA purification column obtained in step 1,12000 revs/min
Clock is centrifuged 30s, removes the first filtrate;Continue that 600 the second buffers of μ L are added to the RNA purification column, 12000 revs/min,
It is centrifuged 30s, removes the second filtrate;
Step 3:5 μ 10 × DNA enzymatic of L buffers, 4 μ L recombinant dnases are taken, 41 μ L go the distilled water of RNA enzyme through mixing
To DNA enzymatic reaction solution, 50 μ L DNA enzymatic reaction solutions are added into the RNA purification column after removing second filtrate, are stored at room temperature
15 minutes, the second buffer described in 350 μ L is added, 12000 revs/min, is centrifuged 30s, removes third filtrate;
Step 4:The RNA purification column that third filtrate is removed in step 3 is placed in 1.5mL without RNA hydrolase collecting pipe, to
The distilled water for removing RNA hydrolase of 50 μ L is added in RNA purification column or 0.1% pyrocarbonic acid diethyl ester handles water, is stored at room temperature 5 points
Clock, is centrifuged 2min, eluted rna purification column, using the OD260/OD280 of spectrophotometer measurement RNA solution by 12000 revs/min
When ratio is 1.7~2.1, RNA is obtained.
Or the method that RNA is extracted from nasal cavity cast-off cells, include the following steps:
Step 1:Genomic DNA adsorption column is taken to be placed in 2mL collecting pipe, the nasal cavity cast-off cells are dissolved in 100~
It is added after in 2000 μ L cell pyrolysis liquids into genomic DNA adsorption column, takes filtrate, isometric 70% is added into the filter
Ethyl alcohol is added after mixing into RNA purification column, 12000 revs/min, is centrifuged 1min, is removed filtrate, the RNA is purified
Column is placed in 2mL collecting pipe;
Step 2:It is added the first buffer of 500 μ L into the RNA purification column obtained in step 1,12000 revs/min
Clock is centrifuged 30s, removes the first filtrate;Continue that 600 the second buffers of μ L are added to the RNA purification column, 12000 revs/min,
It is centrifuged 30s, removes the second filtrate;
Step 3:The RNA purification column that the second filtrate is removed in step 2 is placed in 1.5mL without RNA hydrolase collecting pipe, to
The distilled water for removing RNA hydrolase of 50 μ L is added in RNA purification column or 0.1% pyrocarbonic acid diethyl ester handles water, is stored at room temperature 5 points
Clock, is centrifuged 2min, eluted rna purification column, using the OD260/OD280 of spectrophotometer measurement RNA solution by 12000 revs/min
When ratio is 1.7~2.1, RNA is obtained.
Wherein step 1 can be crushed rapidly nasal cavity cast-off cells using cell pyrolysis liquid and nasal cavity cast-off cells is inhibited to discharge
The substance of nuclease out;Step 1 is using genomic DNA adsorption column for removing genomic DNA;RNA purification column in step 2
For being enriched with RNA;Wherein collecting pipe is used to collect the solution after removal genomic DNA, for removing the purification column for being adsorbed with RNA
Impurity the first buffer, the second buffer for removing impurity and salinity in RNA solution.
In an alternative embodiment, the second method of RNA is extracted from nasal cavity cast-off cells, is included the following steps:To
In centrifuge tube equipped with nasal cavity cast-off cells be added 0.1mL~20mL RNA extract dissolved, vibrate after the RNA is added
0.1~0.5 times of chloroform of extract volume, concussion mix, are stored at room temperature, the centrifuge tube is centrifuged, take supernatant, are added
0.5~3 times of isopropanol of the chloroform volume stands after mixing, is centrifuged, abandons supernatant, retains the first precipitating, to described first
The ethyl alcohol of 0.5~5 times of concentration 65%~90% of the isopropanol volume is added in precipitating, mixes, centrifugation, abandons after washed
Supernatant retains the second precipitating;The centrifuge tube is covered tightly, is centrifuged again, supernatant is removed, continues to be added into the centrifuge tube
0.01~5mL goes RNA enzyme and the water of DNA enzymatic is gone to dissolve second precipitating, using spectrophotometer measurement RNA purity, obtains
RNA。
It is preferred that the RNA extract is Trizol, RNAiso Blood, RNAiso Plus or other contain phenol, different sulphur
The reagent of any one or more of cyanic acid guanidine, 8-hydroxyquinoline, guanidinium isothiocyanate and beta -mercaptoethanol.
In a preferred embodiment, the second method that RNA is extracted from nasal cavity cast-off cells, including following step
Suddenly:After into the centrifuge tube equipped with nasal cavity cast-off cells, addition 0.1~20mLRNA extract is dissolved, vibrated, it is stored at room temperature
3~7min;It is added 40 μ L~5mL chloroforms, concussion mixes, it is stored at room temperature 3~7min, in 3 DEG C~5 DEG C, 10000~14000r/
Min is centrifuged 10~20min;40 μ L~8mL of supernatant is taken, isometric isopropanol is added, 8~12min is stood after mixing, in 3
DEG C~5 DEG C, 10000~14000r/min is centrifuged 10~20min and abandons supernatant, retains the first precipitating;Add into first precipitating
The ethyl alcohol for entering the concentration 65%~90% isometric with isopropanol, in 3 DEG C~5 DEG C, 7000~14000r/min centrifugation 10~
20min abandons supernatant, retains the second precipitating;The centrifuge tube is covered tightly, in 3 DEG C~5 DEG C, 7000~14000r/min centrifugation 1~
3min removes supernatant, continues 0.01~5mL of addition into the centrifuge tube after 10~20min of standing and goes RNA enzyme and remove DNA
The water dissolution of enzyme second precipitating, using spectrophotometer measurement RNA purity, obtains RNA.
Specifically, extracting the second method of RNA from nasal cavity cast-off cells, include the following steps:It is taken off to equipped with nasal cavity
It falls in the centrifuge tube of cell and is added after 1mLRNA extract dissolved, vibrated, be stored at room temperature 5min;200 μ L chloroforms are added, shake
Mixing is swung, 5min is stored at room temperature, in 4 DEG C, 12000r/min is centrifuged 15min;200 μ L of supernatant is taken, 200 μ L isopropanols are added,
10min is stood after mixing, in 4 DEG C, 12000r/min is centrifuged 15min and abandons supernatant, retains the first precipitating;Into first precipitating
The ethyl alcohol with the isometric concentration 75% of isopropanol is added, in 4 DEG C, 7500r/min is centrifuged 15min, abandons supernatant, and it is heavy to retain second
It forms sediment;Cover tightly the centrifuge tube, in 4 DEG C, 7500r/min is centrifuged 2min, removes supernatant, stand continue after 15min to it is described from
50 μ L are added in heart pipe to go RNA enzyme and the water of DNA enzymatic is gone to dissolve second precipitating, using spectrophotometer measurement RNA solution
OD260/OD280 ratio is 1.7~2.1, obtains RNA.
Preferably, the method that total serum IgE reverse transcription is cDNA is included the following steps:The reverse transcription of 1~3 μ L is taken to mix
Liquid, 0~10 μ L go RNA hydrolase distilled water and the RNA of extraction to issue raw reverse transcription reaction 15min in 37 DEG C of temperature conditions,
The inactivation reaction for issuing raw reverse transcriptase in 84 DEG C of temperature conditions afterwards, obtains reverse transcription product cDNA.
In an alternative embodiment, the method that total serum IgE reverse transcription is cDNA is included the following steps:Take that 2 μ L's is described inverse
Mixed liquor is transcribed, the described of 8 μ L goes RNA hydrolase distilled water and total amount total no more than 8 μ L no more than 500ng or volume
RNA, it is described to go RNA hydrolase distilled water polishing to 10 μ L;Reverse transcription reaction is carried out after soft mixing, condition is as follows:At 37 DEG C
Under conditions of, carry out 15 minutes reverse transcription reactions;Under conditions of 85 DEG C, the inactivation reaction of 5 seconds reverse transcriptase is carried out;It produces
4 DEG C of object placements.
In an alternative embodiment, the real-time fluorescence quantitative PCR amplification includes the following steps:
Step 1:Prepare real-time fluorescence quantitative PCR reaction solution:PCR premix including 1 μ of μ L~25 L, 0 μ of μ L~10 L
Distilled water polishing total volume water to 10 μ L, 0 μ of μ L~2 L machine fluorescence compensation and corrigent, 0.01~100 μM
The upstream primer of ALOX15 gene, the downstream primer of 0.01~100 μM of ALOX15 gene, 0.01~100 μM of reference gene
Upstream primer, the downstream primer of 0.01~100 μM of reference gene, the cDNA of 0.01 μ of μ L~5 L;
Step 2:It is fixed that real-time fluorescence is carried out using two-step method PCR amplification standardization program or three-step approach PCR amplification standardization program
Measure PCR detection;
Step 3:Calculate ALOX15 gene expression amount.
Specifically, preparing real-time fluorescence quantitative PCR reaction solution:The distilled water of PCR premix including 5 μ L, 2.8 μ L is mended
Machine fluorescence compensation and corrigent of the neat total volume water to 10 μ L, 0.2 μ L, the upstream primer of the ALOX15 gene of 0.5 μ L,
Draw in the downstream of the downstream primer of the ALOX15 gene of 0.5 μ L, the upstream primer of the reference gene of 0.5 μ L, the reference gene of 0.5 μ L
Object, the cDNA of 1ng/ μ L.
In an alternative embodiment, the reaction condition of the two-step method PCR amplification standardization program includes the following steps:1st
Stage:The initial denaturation 30 seconds under conditions of 95 DEG C;The reaction of 2nd stage PCR:Under conditions of 95 DEG C, react 15 seconds, at 60 DEG C
Under the conditions of, it reacts 60 seconds, annealing extends, and so carries out 40 circulations;
The reaction condition of the three-step approach PCR amplification standardization program includes the following steps:1st stage:In 95 DEG C of condition
Lower initial denaturation 2 minutes;The reaction of 2nd stage PCR:It under conditions of 95 DEG C, reacts 1 minute, under conditions of 55 DEG C, reacts 1 point
Clock reacts 1 minute under conditions of 72 DEG C, so carries out 40 circulations;Last 72 DEG C, annealing in 7 minutes extends;
The method for calculating the ALOX15 gene expression amount is:Calculate Δ CT or 2-ΔΔCTTo calculate the expression of target gene
Amount;Wherein Δ CT=(CT (ALOX15)-CT (GAPDH)) ,-Δ Δ CT=- (Δ CT (processing sample CT (ALOX15)-CT
(GAPDH))-healthy control group average delta CT);The each control group Δ CT of healthy control group average delta CT=∑ (CT (ALOX15)-
CT (GAPDH))/control group sample number.Using Δ CT method or 2-ΔΔCtThe relative quantification method of method, has selected expression quantity relative constant
Reference gene, be standardized with the quantity of reference gene, pass through measurement sample target gene and reference gene Ct value difference
Different calculating destination gene expression amount, method is easy quickly, and detection accuracy is high, can reduce testing cost, saves detection time.As a result
The advantages that convenient for interpretation.Greatly improve conventional efficient.
Specifically be directed to same subject ALOX15 and reference gene expression difference, reference gene be in vivo expression compared with
Stable gene will not usually change with disease etc., therefore be able to reflect target gene and reference gene compared with reference gene
Relative abundance, then Δ CT method can be used.It then can be used for the expression difference of different subject ALOX15 and reference gene
2-ΔΔCtMethod.
The method of ALOX15 gene expression amount is in preparation for detecting with nose in a kind of above-mentioned detection nasal cavity cast-off cells
Application in the kit of the chronic nasosinusitis hypotype of polyp.
ALOX15 in a kind of detection nasal cavity cast-off cells provided by the embodiment of the present invention is introduced in detail in order to become apparent from
The method and application of gene expression amount, are described below in conjunction with specific embodiment.
Embodiment 1:
The collection and processing of sample:
After certain patient normal saline flushing nasal cavity, with hairbrush (production of Copan company) in nasal polyp surface under nasal endoscopes
30s, 3~4 circle of rotation are pressed, hairbrush is placed in by lysate by swipe polyp surface, 4 DEG C of short-term preservations (being no more than 24 hours),
Or it is transferred to lower than -20 DEG C of long-term preservations.
A method of ALOX15 gene expression amount in detection nasal cavity cast-off cells includes the following steps:
Step 1:RNA is extracted from nasal cavity cast-off cells:
Step 1:It takes genomic DNA adsorption column to be placed in 2mL collecting pipe, the nasal cavity cast-off cells is dissolved in 300 μ L
It is added after in cell pyrolysis liquid into genomic DNA adsorption column, takes filtrate, 70% isometric ethyl alcohol is added into the filter,
It is added after mixing into RNA purification column, 12000 revs/min, is centrifuged 1min, removed filtrate, the RNA purification column is set
In 2mL collecting pipe;
Step 2:It is added the first buffer of 500 μ L into the RNA purification column obtained in step 1,12000 revs/min
Clock is centrifuged 30s, removes the first filtrate;Continue that 600 the second buffers of μ L are added to the RNA purification column, 12000 revs/min,
It is centrifuged 30s, removes the second filtrate;
Step 3:The RNA purification column that the second filtrate is removed in step 2 is placed in 1.5mL without RNA hydrolase collecting pipe, to
The distilled water for removing RNA hydrolase of 50 μ L is added in RNA purification column or 0.1% pyrocarbonic acid diethyl ester handles water, is stored at room temperature 5 points
Clock, is centrifuged 2min, eluted rna purification column, using the OD260/OD280 of spectrophotometer measurement RNA solution by 12000 revs/min
Ratio is 2.0, obtains RNA;
Step 2:Reverse transcription prepares cDNA, includes the following steps:Take the reverse transcription mixed liquor of 2 μ L, the institute of 0~8 μ L
RNA hydrolase distilled water is stated (to be no more than 500ng according to RNA amount water polishing to 8 μ L) and total amount or volume is no more than 8 μ
The total serum IgE of L, it is described to go RNA hydrolase distilled water polishing to 10 μ L;Reverse transcription reaction is carried out after soft mixing, condition is as follows:?
Under conditions of 37 DEG C, 15 minutes reverse transcription reactions are carried out;Under conditions of 85 DEG C, the inactivation for carrying out 5 seconds reverse transcriptase is anti-
It answers;4 DEG C of product placements.
Step 3:Real-time fluorescence quantitative PCR augmentation detection, includes the following steps:
Step 1:Prepare real-time fluorescence quantitative PCR reaction solution:PCR premix including 1 μ L, the distilled water of 0-10 μ L
(according to total volume water polishing to 10 μ L), the machine fluorescence compensation of 0.2 μ L and corrigent, the upstream of 1 μM of ALOX15 gene
Primer, the downstream primer of 1 μM of ALOX15 gene, the downstream of the upstream primer of 1 μM of reference gene, 1 μM of reference gene is drawn
Object, the cDNA of 0.01 μ L, the positive control of 1 μ g, the negative control of 1 μ g, positive control are the plasmids containing ALOX15, yin
Property control be empty plasmid (plasmid vector);
Step 2:Using two-step method PCR amplification standardization program:The reaction condition packet of the two-step method PCR amplification standardization program
Include following steps:1st stage:The initial denaturation 30 seconds under conditions of 95 DEG C;The reaction of 2nd stage PCR:Under conditions of 95 DEG C, instead
It answers 15 seconds, under conditions of 60 DEG C, reacts 60 seconds, annealing extends, and so carries out 40 circulations.
Step 4:Calculate the ALOX15 gene expression amount:
The amplification curve and melting curve for confirming real-time fluorescence quantitative PCR after reaction, read ALOX15's and GAPDH
Ct value selects △ Ct analytic approach (the Ct value of ALOX15 subtracts the Ct value of GAPDH) to be analyzed, using GAPDH as reference gene;
Positive control Ct value<20 and negative control Ct value>38 are considered as experiment effectively, and otherwise experiment is invalid;
Compare the expression difference of ALOX15 and reference gene using Δ CT method:The mean CT-number of ALOX15 is
20.9, GAPDH mean CT-number is 18.9, and Δ CT value is 2.0.
Embodiment 2:
The collection and processing of sample:
After certain patient normal saline flushing nasal cavity, with hairbrush (production of Copan company) in nasal polyp surface under nasal endoscopes
30s, 3~4 circle of rotation are pressed, hairbrush is placed in by lysate by swipe polyp surface, 4 DEG C of short-term preservations (being no more than 24 hours),
Or it is transferred to lower than -20 DEG C of long-term preservations.
A method of ALOX15 gene expression amount in detection nasal cavity cast-off cells includes the following steps:
Step 1:RNA is extracted from nasal cavity cast-off cells:
Step 1:It takes genomic DNA adsorption column to be placed in 2mL collecting pipe, the nasal cavity cast-off cells is dissolved in 100 μ L
It is added after in cell pyrolysis liquid into genomic DNA adsorption column, is centrifuged 60s under conditions of 12000 turns/min, takes filtrate, to
70% isometric ethyl alcohol is added in the filter, is added after mixing into RNA purification column, 12000 revs/min, centrifugation
1min removes filtrate, the RNA purification column is placed in 2mL collecting pipe;
Step 2:It is added the first buffer of 300 μ L into the RNA purification column obtained in step 1,12000 revs/min
Clock is centrifuged 30s, removes the first filtrate;Continue that 400 the second buffers of μ L are added to the RNA purification column, 12000 revs/min,
It is centrifuged 30s, removes the second filtrate;
Step 3:The RNA purification column that the second filtrate is removed in step 2 is placed in 1.5mL without RNA hydrolase collecting pipe, to
The distilled water for removing RNA hydrolase of 50 μ L is added in RNA purification column or 0.1% pyrocarbonic acid diethyl ester handles water, is stored at room temperature 5 points
Clock, is centrifuged 2min, eluted rna purification column, using the OD260/OD280 of spectrophotometer measurement RNA solution by 12000 revs/min
Ratio is 2.0, obtains RNA;
Step 2:Reverse transcription prepares cDNA, includes the following steps:The reverse transcription mixed liquor of 1 μ L is taken, 0~10 μ L's
It is described that RNA hydrolase distilled water and total amount is gone to be no more than the total serum IgE of 500ng or volume no more than 8 μ L, it is described that RNA is gone to hydrolyze
Enzyme distilled water polishing is to 10 μ L;Reverse transcription reaction is carried out after soft mixing, condition is as follows:Under conditions of 37 DEG C, 15 points are carried out
The reverse transcription reaction of clock;Under conditions of 85 DEG C, the inactivation reaction of 5 seconds reverse transcriptase is carried out;4 DEG C of product placements.
Step 3:Real-time fluorescence quantitative PCR augmentation detection, includes the following steps:
Step 1:Prepare real-time fluorescence quantitative PCR reaction solution:PCR premix including 25 μ L, the distilled water of 0~10 μ L
(according to total volume water polishing to 10 μ L), the dyestuff (fluorescence for carrying out machine compensates and correction) of 0~2 μ L, 0.01 μM
ALOX15 gene upstream primer, the downstream primer of 0.01 μM of ALOX15 gene, the upstream of 0.01 μM of reference gene is drawn
Object, the downstream primer of 0.01 μM of reference gene, the cDNA of 5 μ L, 1 μ g positive control, 1 μ g negative control, positive control is to contain
There is the plasmid of ALOX15, negative control is empty plasmid (plasmid vector);
Step 2:Using two-step method PCR amplification standardization program:The reaction condition packet of the two-step method PCR amplification standardization program
Include following steps:1st stage:The initial denaturation 30 seconds under conditions of 95 DEG C;The reaction of 2nd stage PCR:Under conditions of 95 DEG C, instead
It answers 15 seconds, under conditions of 60 DEG C, reacts 60 seconds, annealing extends, and so carries out 40 circulations.
Step 4:Calculate the ALOX15 gene expression amount:
The amplification curve and melting curve for confirming real-time fluorescence quantitative PCR after reaction, read ALOX15's and GAPDH
Ct value selects △ Ct analytic approach (the Ct value of ALOX15 subtracts the Ct value of GAPDH) to be analyzed, using GAPDH as reference gene;
Positive control Ct value<20 and negative control Ct value>38 are considered as experiment effectively, and otherwise experiment is invalid;
Compare the expression difference of ALOX15 and reference gene using Δ CT method:The mean CT-number of ALOX15 is
19.5, GAPDH mean CT-number is 18.0, and Δ CT value is 1.5.
Embodiment 3:
The collection and processing of sample:
After certain patient normal saline flushing nasal cavity, with hairbrush (production of Copan company) in nasal polyp surface under nasal endoscopes
30s, 3~4 circle of rotation are pressed, hairbrush is placed in by lysate by swipe polyp surface, 4 DEG C of short-term preservations (being no more than 24 hours),
Or it is transferred to lower than -20 DEG C of long-term preservations.
A method of ALOX15 gene expression amount in detection nasal cavity cast-off cells includes the following steps:
Step 1:RNA is extracted from nasal cavity cast-off cells:
Step 1:It takes genomic DNA adsorption column to be placed in 2mL collecting pipe, the nasal cavity cast-off cells is dissolved in 2000 μ L
It is added after in cell pyrolysis liquid into genomic DNA adsorption column, is centrifuged 60s under conditions of 12000 turns/min, takes filtrate, to
70% isometric ethyl alcohol is added in the filter, is added after mixing into RNA purification column, 12000 revs/min, centrifugation
1min removes filtrate, the RNA purification column is placed in 2mL collecting pipe;
Step 2:It is added the first buffer of 700 μ L into the RNA purification column obtained in step 1,12000 revs/min
Clock is centrifuged 30s, removes the first filtrate;Continue that 800 the second buffers of μ L are added to the RNA purification column, 12000 revs/min,
It is centrifuged 30s, removes the second filtrate;
Step 3:The RNA purification column that the second filtrate is removed in step 2 is placed in 1.5mL without RNA hydrolase collecting pipe, to
The distilled water for removing RNA hydrolase of 50 μ L is added in RNA purification column or 0.1% pyrocarbonic acid diethyl ester handles water, is stored at room temperature 5 points
Clock, is centrifuged 2min, eluted rna purification column, using the OD260/OD280 of spectrophotometer measurement RNA solution by 12000 revs/min
Ratio is 2.0, obtains RNA;
Step 2:Reverse transcription prepares cDNA, includes the following steps:The reverse transcription mixed liquor of 3 μ L is taken, 0~8 μ L is gone
RNA enzyme and the water of DNA enzymatic is gone (to be no more than 500ng according to RNA amount water polishing to 8 μ L) and total amount or volume is no more than 8 μ L
Total serum IgE, it is described to go RNA hydrolase distilled water polishing to 10 μ L;Reverse transcription reaction is carried out after soft mixing, condition is as follows:?
Under conditions of 37 DEG C, 15 minutes reverse transcription reactions are carried out;Under conditions of 85 DEG C, the inactivation for carrying out 5 seconds reverse transcriptase is anti-
It answers;4 DEG C of product placements.
Step 3:Real-time fluorescence quantitative PCR augmentation detection, includes the following steps:
Step 1:Prepare real-time fluorescence quantitative PCR reaction solution:It is (gentle containing enzyme required for PCR including 5 μ L premixs
Fliud flushing), (according to total volume with water polishing to 10 μ L), the dyestuff of 0~2 μ L is (for carrying out the glimmering of machine for the distilled water of 0-10 μ L
Light compensation and correction), the upstream primer of 1 μM of ALOX15 gene, the downstream primer of 1 μM of ALOX15 gene, 1 μM of internal reference base
The upstream primer of cause, the downstream primer of 1 μM of reference gene, the cDNA of 2 μ L, 1 μ g positive control, 1 μ g negative control;
Step 2:Using two-step method PCR amplification standardization program:The reaction condition packet of the two-step method PCR amplification standardization program
Include following steps:1st stage:The initial denaturation 30 seconds under conditions of 95 DEG C;The reaction of 2nd stage PCR:Under conditions of 95 DEG C, instead
It answers 15 seconds, under conditions of 60 DEG C, reacts 60 seconds, annealing extends, and so carries out 40 circulations.
Step 4:Calculate the ALOX15 gene expression amount:
The amplification curve and melting curve for confirming real-time fluorescence quantitative PCR after reaction, read ALOX15's and GAPDH
Ct value selects △ Ct analytic approach (the Ct value of ALOX15 subtracts the Ct value of GAPDH) to be analyzed, using GAPDH as reference gene;
Positive control Ct value<20 and negative control Ct value>38 are considered as experiment effectively, and otherwise experiment is invalid;
Compare the expression difference of ALOX15 and reference gene using Δ CT method:The mean CT-number of ALOX15 is
20.1, GAPDH mean CT-number is 17.9, and Δ CT value is 2.2.
In the above embodiment of the present invention 1~3, the manufacturer of preferred first buffer RWA buffer used is
Takara company, article No. 9767;The manufacturer of second buffer RWB buffer is Takara company, article No. 9767.But this
Application protection scope is simultaneously confined to above-mentioned the first buffer and the second buffer.Those skilled in the art can be according to practical application
It is selected.
Embodiment 4:
The collection and processing of sample:
After 78 subjects normal saline flushing nasal cavity, with hairbrush (production of Copan company) in nasal polyp under nasal endoscopes
Surface presses 30s, rotation 3-4 circle, and hairbrush is placed in the subsequent lysate by swipe polyp surface, and 4 DEG C of short-term preservations are (no
More than 24 hours), or be transferred to lower than -20 DEG C of long-term preservations.
A method of ALOX15 gene expression amount in detection nasal cavity cast-off cells includes the following steps:
Step 1:RNA is extracted from nasal cavity cast-off cells:1mLRNA is added into the centrifuge tube equipped with nasal cavity cast-off cells
After extract is dissolved, vibrated, it is stored at room temperature 5min;200 μ L chloroforms are added, concussion mixes, it is stored at room temperature 5min, in 4 DEG C,
12000r/min is centrifuged 15min;200 μ L of supernatant is taken, 200 μ L isopropanols are added, stand 10min after mixing, in 4 DEG C,
12000r/min is centrifuged 15min and abandons supernatant, retains the first precipitating;To it is described first precipitating in be added with isopropanol in equal volume it is dense
The ethyl alcohol of degree 75%, in 4 DEG C, 7500r/min is centrifuged 15min, abandons supernatant, retains the second precipitating;The centrifuge tube is covered tightly, in 4
DEG C, 7500r/min is centrifuged 2min, removes supernatant, stands to continue 50 μ L are added into the centrifuge tube after 15min and goes RNA enzyme
And the water of DNA enzymatic is gone to dissolve second precipitating, use spectrophotometer measurement RNA solution OD260/OD280 ratio for 1.8,
Obtain RNA;
Step 2:Reverse transcription prepares cDNA step with embodiment one.
Step 3:Real-time fluorescence quantitative PCR augmentation detection step is the same as embodiment one.
Step 4:Calculate the ALOX15 gene expression amount:
The amplification curve and melting curve for confirming real-time fluorescence quantitative PCR after reaction, read ALOX15's and GAPDH
Ct value selects △ Ct analytic approach (the Ct value of ALOX15 subtracts the Ct value of GAPDH) to be analyzed, using GAPDH as reference gene;
Positive control Ct value<20 and negative control Ct value>38 are considered as experiment effectively, and otherwise experiment is invalid;
Step 1:Calculate healthy control group average delta CT:Subject 1~10 is healthy control group in this example, and calculation method is such as
Under:Average delta CT (CT (ALOX15)-CT (GAPDH))=(1.754+1.655+1.829+2.2+1.308+1.449+1.234+
1.343+1.49+1.695/10=1.5975;
Step 2:Calculate subject's relative expression quantity:
On the basis of 1.5975, finding out each subject's relative expression quantity (indicates Ben Jiyin relative healths in subject
Compare cell mean expression height, numerical value represent variation multiple, such as 1.5 be equivalent to the subject expression quantity be health it is right
According to 1.5 times of cell mean), calculated result is as shown in table 1.
Calculation formula is 2-ΔΔCT,-Δ Δ CT=- (Δ CT (subject CT (ALOX15)-CT (GAPDH))-average delta CT
(healthy control group average delta CT)).
The ALOX15 gene expression amount calculated result for the method that 1 embodiment 2 of table provides
Embodiment 5:
The collection and processing of sample:
Patient's normal saline flushing nasal cavity is advised before obtaining cell, with hairbrush (production of Copan company) in nose under nasal endoscopes
Polyp surface presses 30s, rotation 3-4 circle, and hairbrush is placed in lysate by swipe polyp surface, and 4 DEG C of short-term preservations (are no more than
24 hours), or be transferred to lower than -20 DEG C of long-term preservations.
A method of ALOX15 gene expression amount in detection nasal cavity cast-off cells includes the following steps:
Step 1:RNA step is extracted from nasal cavity cast-off cells:It is added into the centrifuge tube equipped with nasal cavity cast-off cells
After 20mLRNA extract is dissolved, vibrated, it is stored at room temperature 7min;10mL chloroform is added, concussion mixes, it is stored at room temperature 7min,
In 5 DEG C, 14000r/min is centrifuged 20min;Supernatant 20mL is taken, the isopropanol of 20mL is added, 12min is stood after mixing, in 5
DEG C, 14000r/min is centrifuged 20min and abandons supernatant, retains the first precipitating;The concentration 90% of 40mL is added into first precipitating
Ethyl alcohol, in 5 DEG C, 14000r/min is centrifuged 3min, abandons supernatant, retains the second precipitating;The centrifuge tube is covered tightly, in 5 DEG C,
14000r/min is centrifuged 3min, removes supernatant, continues the addition 5mL into the centrifuge tube after standing 20min and goes RNA enzyme and go
The water dissolution of DNA enzymatic second precipitating, uses spectrophotometer measurement RNA solution OD260/OD280 ratio to obtain for 2.1
RNA;
Step 2:Reverse transcription prepares cDNA step with embodiment one.
Step 3:Real-time fluorescence quantitative PCR reaction solution is prepared with implementation in real-time fluorescence quantitative PCR augmentation detection step
Example one, for PCR amplification standardization program use three-step approach, the reaction condition of the three-step approach PCR amplification standardization program include with
Lower step:1st stage:The initial denaturation 2 minutes under conditions of 95 DEG C;The reaction of 2nd stage PCR:Under conditions of 95 DEG C, reaction 1
Minute, it under conditions of 55 DEG C, reacts 1 minute, under conditions of 72 DEG C, reacts 1 minute, so carry out 40 circulations;Finally
72 DEG C, annealing in 7 minutes extends.
Step 4:Calculate the ALOX15 gene expression amount:
The amplification curve and melting curve for confirming real-time fluorescence quantitative PCR after reaction, read ALOX15's and GAPDH
Ct value selects △ Ct analytic approach (the Ct value of ALOX15 subtracts the Ct value of GAPDH) to be analyzed, using GAPDH as reference gene;
Positive control Ct value<20 and negative control Ct value>38 are considered as experiment effectively, and otherwise experiment is invalid;
Positive control wells are averaged Ct:16.7;Negative control hole is averaged Ct:38.4;Sample ALOX15 is averaged Ct:21.5;Sample
Product GAPDH is averaged Ct:19.4;Difference value:It is 2.1.Indicate that the patient ALOX15 is expressed as 0.23 times (1/2 of GAPDH2.1)。
Embodiment 6:
The collection and processing of sample:
Patient's normal saline flushing nasal cavity is advised before obtaining cell, with hairbrush (production of Copan company) in nose under nasal endoscopes
Polyp surface presses 30s, rotation 3-4 circle, and hairbrush is placed in lysate by swipe polyp surface, and 4 DEG C of short-term preservations (are no more than
24 hours), or be transferred to lower than -20 DEG C of long-term preservations.
A method of ALOX15 gene expression amount in detection nasal cavity cast-off cells includes the following steps:
Step 1:RNA step is extracted from nasal cavity cast-off cells:It is added into the centrifuge tube equipped with nasal cavity cast-off cells
After 0.1mLRNA extract is dissolved, vibrated, it is stored at room temperature 7min;0.03mL chloroform is added, concussion is mixed, is stored at room temperature
7min, in 5 DEG C, 14000r/min is centrifuged 20min;Supernatant 20mL is taken, the isopropanol of 0.015mL is added, is stood after mixing
12min, in 5 DEG C, 14000r/min is centrifuged 20min and abandons supernatant, retains the first precipitating;It is added into first precipitating
The ethyl alcohol of the concentration 90% of 0.0075mL, in 5 DEG C, 14000r/min is centrifuged 3min, abandons supernatant, retains the second precipitating;Cover tightly institute
Centrifuge tube is stated, in 5 DEG C, 14000r/min is centrifuged 3min, removes supernatant, continues to add into the centrifuge tube after standing 20min
Enter 0.01mL to go RNA enzyme and the water of DNA enzymatic is gone to dissolve second precipitating, using spectrophotometer measurement RNA solution OD260/
OD280 ratio is 2.1, obtains RNA;
Step 2:Reverse transcription prepares cDNA step with embodiment one.
Step 3:Real-time fluorescence quantitative PCR reaction solution is prepared with implementation in real-time fluorescence quantitative PCR augmentation detection step
Example one, for PCR amplification standardization program use three-step approach, the reaction condition of the three-step approach PCR amplification standardization program include with
Lower step:1st stage:The initial denaturation 2 minutes under conditions of 95 DEG C;The reaction of 2nd stage PCR:Under conditions of 95 DEG C, reaction 1
Minute, it under conditions of 55 DEG C, reacts 1 minute, under conditions of 72 DEG C, reacts 1 minute, so carry out 40 circulations;Finally
72 DEG C, annealing in 7 minutes extends.
Step 4:Calculate the ALOX15 gene expression amount:
The amplification curve and melting curve for confirming real-time fluorescence quantitative PCR after reaction, read ALOX15's and GAPDH
Ct value selects △ Ct analytic approach (the Ct value of ALOX15 subtracts the Ct value of GAPDH) to be analyzed, using GAPDH as reference gene;
Positive control Ct value<20 and negative control Ct value>38 are considered as experiment effectively, and otherwise experiment is invalid;
Positive control wells are averaged Ct:15.9;Negative control hole is averaged Ct:38.7;Sample ALOX15 is averaged Ct:17.8;Sample
Product GAPDH is averaged Ct:16.4;Difference value:17.8-16.4 being 1.4.Indicate that the patient ALOX15 is expressed as 0.51 times of GAPDH
(1/21.4)。
Sequence table
<110>It raises
Wang Chengshuo
Yan Bing
Beijing Otorhinolaryngology Inst.
Capital University Of Medical Sciences Affiliated Beijing Tongren Hospital
<120>Detect the method and application of ALOX15 gene expression amount in nasal cavity cast-off cells
<130> CC18K10089CCN
<141> 2018-07-03
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 2715
<212> DNA
<213> human
<400> 1
gagcgaaaca tctttgagca agatgggtct ctaccgcatc cgcgtgtcca ctggggcctc 60
gctctatgcc ggttccaaca accaggtgca gctgtggctg gtcggccagc acggggaggc 120
ggcgctcggg aagcgactgt ggcccgcacg gggcaaggag acagaactca aggtggaagt 180
accggagtat ctggggccgc tgctgtttgt gaaactgcgc aaacggcacc tccttaagga 240
cgacgcctgg ttctgcaact ggatctctgt gcagggcccc ggagccgggg acgaggtcag 300
gttcccttgt taccgctggg tggagggcaa cggcgtcctg agcctgcctg aaggcaccgg 360
ccgcactgtg ggcgaggacc ctcagggcct gttccagaaa caccgggaag aagagctgga 420
agagagaagg aagttgtacc ggtggggaaa ctggaaggac gggttaattc tgaatatggc 480
tggggccaaa ctatatgacc tccctgtgga tgagcgattt ctggaagaca agagagttga 540
ctttgaggtt tcgctggcca aggggctggc cgacctcgct atcaaagact ctctaaatgt 600
tctgacttgc tggaaggatc tagatgactt caaccggatt ttctggtgtg gtcagagcaa 660
gctggctgag cgcgtgcggg actcctggaa ggaagatgcc ttatttgggt accagtttct 720
taatggcgcc aaccccgtgg tgctgaggcg ctctgctcac cttcctgctc gcctagtgtt 780
ccctccaggc atggaggaac tgcaggccca gctggagaag gagctggagg gaggcacact 840
gttcgaagct gacttctccc tgctggatgg gatcaaggcc aacgtcattc tctgtagcca 900
gcagcacctg gctgcccctc tagtcatgct gaaattgcag cctgatggga aactcttgcc 960
catggtcatc cagctccagc tgccccgcac aggatcccca ccacctcccc ttttcttgcc 1020
tacggatccc ccaatggcct ggcttctggc caaatgctgg gtgcgcagct ctgacttcca 1080
gctccatgag ctgcagtctc atcttctgag gggacacttg atggctgagg tcattgttgt 1140
ggccaccatg aggtgcctgc cgtcgataca tcctatcttc aagcttataa ttccccacct 1200
gcgatacacc ctggaaatta acgtccgggc caggactggg ctggtctctg acatgggaat 1260
tttcgaccag ataatgagca ctggtggggg aggccacgtg cagctgctca agcaagctgg 1320
agccttccta acctacagct ccttctgtcc ccctgatgac ttggccgacc gggggctcct 1380
gggagtgaag tcttccttct atgcccaaga tgcgctgcgg ctctgggaaa tcatctatcg 1440
gtatgtggaa ggaatcgtga gtctccacta taagacagac gtggctgtga aagacgaccc 1500
agagctgcag acctggtgtc gagagatcac tgaaatcggg ctgcaagggg cccaggaccg 1560
agggtttcct gtctctttac aggctcggga ccaggtttgc cactttgtca ccatgtgtat 1620
cttcacctgc accggccaac acgcctctgt gcacctgggc cagctggact ggtactcttg 1680
ggtgcctaat gcaccctgca cgatgcggct gcccccgcca accaccaagg atgcaacgct 1740
ggagacagtg atggcgacac tgcccaactt ccaccaggct tctctccaga tgtccatcac 1800
ttggcagctg ggcagacgcc agcccgttat ggtggctgtg ggccagcatg aggaggagta 1860
tttttcgggc cctgagccta aggctgtgct gaagaagttc agggaggagc tggctgccct 1920
ggataaggaa attgagatcc ggaatgcaaa gctggacatg ccctacgagt acctgcggcc 1980
cagcgtggtg gaaaacagtg tggccatcta agcgtcgcca ccctttggtt atttcagccc 2040
ccatcaccca agccacaagc tgaccccttc gtggttatag ccctgccctc ccaagtccca 2100
ccctcttccc atgtcccacc ctccctagag gggcaccttt tcatggtctc tgcacccagt 2160
gaacacattt tactctagag gcatcacctg ggaccttact cctctttcct tccttcctcc 2220
tttcctatct tccttcctct ctctcttcct ctttcttcat tcagatctat atggcaaata 2280
gccacaatta tataaatcat ttcaagacta gaataggggg atataataca tattactcca 2340
caccttttat gaatcaaata tgattttttt gttgttgtta agacagagtc tcactttgac 2400
acccaggctg gagtgcagtg gtgccatcac cacggctcac tgcagcctca gcgtcctggg 2460
ctcaaatgat cctcccacct cagcctcctg agtagctggg actacaggct catgccatca 2520
tgcccagcta atattttttt attttcgtgg agacggggcc tcactatgtt gcctaggctg 2580
gaaataggat tttgaaccca aattgagttt aacaataata aaaagttgtt ttacgctaaa 2640
gatggaaaag aactaggact gaactatttt aaataaaata ttggcaaaag aaaaaaaaaa 2700
aaaaaaaaaa aaaaa 2715
<210> 2
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 2
gggcaaggag acagaactca a 21
<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 3
cagcggtaac aagggaacct 20
<210> 4
<211> 22
<212> DNA
<213> Artificial Sequence
<400> 4
ctcctcctgt tcgacagtca gc 22
<210> 5
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 5
cccaatacga ccaaatccgt t 21
Claims (11)
1. a kind of method of ALOX15 gene expression amount in detection nasal cavity cast-off cells, it is characterised in that:Include the following steps:From
RNA is extracted in nasal cavity cast-off cells, is cDNA by total serum IgE reverse transcription, it will be in cDNA using quantitative polyase chain reaction
The specific primer of ALOX15 gene is respectively adopted in ALOX15 gene and reference gene specific primer and reference gene carries out
Real-time fluorescence quantitative PCR amplification, the testing result based on amplified production calculate ALOX15 gene expression amount.
2. the method for ALOX15 gene expression amount in detection nasal cavity cast-off cells according to claim 1, it is characterised in that:
The upstream primer of ALOX15 gene such as SEQ ID NO:Shown in 2, the downstream primer of ALOX15 gene such as SEQ ID NO:Shown in 3;
The reference gene is GAPDH, the upstream primer of the reference gene such as SEQ ID NO:Shown in 4, the downstream primer
Such as SEQ ID NO:Shown in 5.
3. the method for ALOX15 gene expression amount in detection nasal cavity cast-off cells according to claim 1, it is characterised in that:
The nasal cavity cast-off cells are obtained using hairbrush in nasal polyp surface, and the hairbrush that will acquire after nasal cavity cast-off cells is placed in cell
It is saved in lysate in 4 DEG C or less.
4. the method for ALOX15 gene expression amount in detection nasal cavity cast-off cells according to claim 1, it is characterised in that:
The method that RNA is extracted from nasal cavity cast-off cells, includes the following steps:
Step 1:The nasal cavity cast-off cells are dissolved in 100~2000 μ L cell pyrolysis liquids, and isometric ethyl alcohol is added,
It is added after mixing into RNA purification column, after centrifugal treating, removes filtrate, the RNA purification column is placed in collecting pipe;
Step 2:The first buffer of 300 μ of μ L~700 L, centrifugal treating are added into the RNA purification column obtained in step 1
Afterwards, the first filtrate is removed;Continue that 400 μ of μ L~800 the second buffers of L are added to the RNA purification column, after centrifugal treating, removes
Second filtrate takes RNA purification column through affording RNA.
5. the method for ALOX15 gene expression amount in detection nasal cavity cast-off cells according to claim 4, it is characterised in that:
The method that RNA is extracted from nasal cavity cast-off cells, it is further comprising the steps of:RNA purification column to after removing second filtrate
After stewing process the second buffer described in 300 μ of μ L~700 L is added, at centrifugation in 10~100 μ LDNA enzyme reaction solutions of middle addition
After reason, third filtrate is removed, RNA purification column is taken, using spectrophotometer measurement RNA purity, to obtain RNA after eluting;
The preparation method of the DNA enzymatic reaction solution includes the following steps:DNA enzymatic buffer, recombinant dnase are taken, the double of RNA enzyme are gone
It steams water and is mixed to get DNA enzymatic reaction solution.
6. the method for ALOX15 gene expression amount in detection nasal cavity cast-off cells according to claim 4, it is characterised in that:
The method that RNA is extracted from nasal cavity cast-off cells, it is further comprising the steps of:In the step 1, the nasal cavity cast-off cells dissolution
It is first added after in cell pyrolysis liquid into genomic DNA adsorption column and takes filtrate, then isometric second is added into the filtrate
Alcohol.
7. the method for ALOX15 gene expression amount in detection nasal cavity cast-off cells according to any one of claim 4 to 6,
It is characterized in that:The method that RNA is extracted from nasal cavity cast-off cells, it is further comprising the steps of:RNA purification column to be eluted is taken to be added
The distilled water or pyrocarbonic acid diethyl ester processing water for removing RNA hydrolase, after being stored at room temperature, purify through centrifugal treating, the elution RNA
Column obtains RNA using spectrophotometer measurement RNA purity.
8. the method for ALOX15 gene expression amount in detection nasal cavity cast-off cells according to claim 1, it is characterised in that:
The method that RNA is extracted from nasal cavity cast-off cells, includes the following steps:It is added into the centrifuge tube equipped with nasal cavity cast-off cells
0.1mL~20mLRNA extract dissolved, vibrate after 0.1~0.5 times of chloroform of the RNA extract volume, shake is added
Mixing is swung, is stored at room temperature, the centrifuge tube is centrifuged, supernatant is taken, 0.5~3 times of isopropanol of the chloroform volume is added,
After mixing stand, be centrifuged, abandon supernatant, retain first precipitating, to it is described first precipitating in be added the isopropanol volume 0.5~
The ethyl alcohol of 5 times of concentration 65%~90% mixes, centrifugation after washed, abandons supernatant, retains the second precipitating;Centrifuge tube is covered tightly, then
Secondary centrifugation removes supernatant, continues 0.01~5mL of addition into the centrifuge tube and goes RNA enzyme and go described in the water dissolution of DNA enzymatic
Second precipitating, using spectrophotometer measurement RNA purity, obtains RNA;
The RNA extract be Trizol, RNAiso Blood, RNAiso Plus or other containing phenol, guanidinium isothiocyanate,
The reagent of any one or more of 8-hydroxyquinoline, guanidinium isothiocyanate and beta -mercaptoethanol.
9. the method for ALOX15 gene expression amount in detection nasal cavity cast-off cells according to claim 1, it is characterised in that:
The method that total serum IgE reverse transcription is cDNA is included the following steps:The reverse transcription mixed liquor of 1~3 μ L, 0~10 μ L is taken to go
RNA hydrolase distilled water and the RNA of extraction issue raw reverse transcription reaction 15min in 37 DEG C of temperature conditions, after in 84 DEG C of temperature strips
The inactivation reaction that reverse transcriptase occurs under part, obtains reverse transcription product cDNA;
The real-time fluorescence quantitative PCR amplification includes the following steps:
Step 1:Prepare real-time fluorescence quantitative PCR reaction solution:PCR premix including 1 μ of μ L~25 L, 0 μ of μ L~10 L's is double
Steam machine fluorescence compensation and corrigent of the water polishing total volume water to 10 μ L, 0 μ of μ L~2 L, 0.01~100 μM of ALOX15 base
The upstream primer of cause, the downstream primer of 0.01~100 μM of ALOX15 gene, the upstream of 0.01~100 μM of reference gene is drawn
Object, the downstream primer of 0.01~100 μM of reference gene, the cDNA of 0.01 μ of μ L~5 L;
Step 2:Real-time fluorescence quantitative PCR is carried out using two-step method PCR amplification standardization program or three-step approach PCR amplification standardization program
Detection;
Step 3:Calculate ALOX15 gene expression amount.
10. the method for ALOX15 gene expression amount, feature exist in detection nasal cavity cast-off cells according to claim 9
In:The reaction condition of the two-step method PCR amplification standardization program includes the following steps:1st stage:Become in advance under conditions of 95 DEG C
Property 30 seconds;The reaction of 2nd stage PCR:It under conditions of 95 DEG C, reacts 15 seconds, under conditions of 60 DEG C, reacts 60 seconds, annealing is prolonged
It stretches, so carries out 40 circulations;
The reaction condition of the three-step approach PCR amplification standardization program includes the following steps:1st stage:It is pre- under conditions of 95 DEG C
Denaturation 2 minutes;The reaction of 2nd stage PCR:It under conditions of 95 DEG C, reacts 1 minute, under conditions of 55 DEG C, reacts 1 minute,
It under conditions of 72 DEG C, reacts 1 minute, so carries out 40 circulations;Last 72 DEG C, annealing in 7 minutes extends;
The method for calculating the ALOX15 gene expression amount is:Calculate Δ CT or 2-ΔΔCTTo calculate the expression quantity of target gene;Its
Middle Δ CT=(CT (ALOX15)-CT (GAPDH)) ,-Δ Δ CT=- (Δ CT (processing sample CT (ALOX15)-CT (GAPDH))-
Healthy control group average delta CT);The each control group Δ CT of healthy control group average delta CT=∑ (CT (ALOX15)-CT
(GAPDH))/control group sample number.
11. a kind of method of ALOX15 gene expression amount in described in any item detection nasal cavity cast-off cells of claim 1~10
In preparation for detecting the application in the kit with the chronic nasosinusitis hypotype of nasal polyp.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810720285.4A CN108913764A (en) | 2018-07-03 | 2018-07-03 | Detect the method and application of ALOX15 gene expression amount in nasal cavity cast-off cells |
PCT/CN2019/093281 WO2020007227A1 (en) | 2018-07-03 | 2019-06-27 | Method and kit for detecting chronic rhinosinusitis with nasal polyps subtype and use of alox15 gene as biomarker |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810720285.4A CN108913764A (en) | 2018-07-03 | 2018-07-03 | Detect the method and application of ALOX15 gene expression amount in nasal cavity cast-off cells |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108913764A true CN108913764A (en) | 2018-11-30 |
Family
ID=64423742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810720285.4A Pending CN108913764A (en) | 2018-07-03 | 2018-07-03 | Detect the method and application of ALOX15 gene expression amount in nasal cavity cast-off cells |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108913764A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020007227A1 (en) * | 2018-07-03 | 2020-01-09 | 首都医科大学附属北京同仁医院 | Method and kit for detecting chronic rhinosinusitis with nasal polyps subtype and use of alox15 gene as biomarker |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102232113A (en) * | 2008-03-31 | 2011-11-02 | 健泰科生物技术公司 | Compositions and methods for treating and diagnosing asthma |
CN105849280A (en) * | 2013-10-23 | 2016-08-10 | 豪夫迈·罗氏有限公司 | Methods of diagnosing and treating eosinophilic disorders |
-
2018
- 2018-07-03 CN CN201810720285.4A patent/CN108913764A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102232113A (en) * | 2008-03-31 | 2011-11-02 | 健泰科生物技术公司 | Compositions and methods for treating and diagnosing asthma |
CN105849280A (en) * | 2013-10-23 | 2016-08-10 | 豪夫迈·罗氏有限公司 | Methods of diagnosing and treating eosinophilic disorders |
Non-Patent Citations (2)
Title |
---|
ROSTKOWSKA-NADOLSKA ET AL: "A microarray study of gene expression profiles in nasal polyps", 《AURIS NASUS LARYNX》 * |
闫冰等: "ALOX15在慢性鼻窦炎伴鼻息肉中表达及糖皮质激素对其作用研究", 《首都医科大学学报》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020007227A1 (en) * | 2018-07-03 | 2020-01-09 | 首都医科大学附属北京同仁医院 | Method and kit for detecting chronic rhinosinusitis with nasal polyps subtype and use of alox15 gene as biomarker |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111004850A (en) | Application of circRNAs molecules in preparation of liver cancer diagnosis kit and kit applying molecules | |
CN103374575B (en) | CYP4V2 gene mutant and application thereof | |
CN106811529A (en) | The fluorescent quantificationally PCR detecting kit and primer of mycobacterium tuberculosis, probe | |
CN108977511A (en) | Detect the method and application of CST1 gene expression amount in nasal cavity cast-off cells | |
CN112575079B (en) | Exosome miRNA (micro ribonucleic acid) serving as molecular marker for diagnosing type 2 diabetes combined coronary heart disease and application of exosome miRNA | |
CN108148908B (en) | Application of molecular marker for diagnosing atherosclerotic renal artery stenosis | |
JP7090357B2 (en) | Use of primer sets, kits, and microRNA serum markers and primer sets to identify the sex of sturgeon | |
CN108913764A (en) | Detect the method and application of ALOX15 gene expression amount in nasal cavity cast-off cells | |
CN109402262A (en) | The PCR detection kit of auxiliary diagnosis neuroblastoma and the method for detecting miR-199a-3p expression | |
CN103374574B (en) | CYP4V2 gene mutant and application thereof | |
WO2019117257A1 (en) | Method for assisting in detection of breast cancer | |
Zhang et al. | Extracellular vesicle-derived miR-26b-5p is up-regulated in the serum of patients with diabetic retinopathy | |
CN108913762A (en) | The application of kit and CST1 gene as biomarker for detecting chronic nasosinusitis with nasal polyp hypotype | |
CN108913763A (en) | Detect the method and application of SAA2 gene expression amount in nasal cavity cast-off cells | |
CN108300788A (en) | A kind of micro RNA combination and its application for detecting light-duty brain trauma | |
US20140378334A1 (en) | Method for quantifying renal markers by assaying urine | |
CN116516008A (en) | Gastric mucosa intestinal epithelium metaplasia marker JUN and application thereof | |
CN116536424A (en) | Application of tRF-19-DRMD5112 in preparation of renal cell carcinoma diagnosis kit | |
CN108977434A (en) | The extracting method of nasal cavity cast-off cells RNA | |
CN112852950B (en) | Acute myocardial infarction biomarker and application thereof | |
CN108977510A (en) | Detect the method and application of CLC gene expression amount in nasal cavity cast-off cells | |
CN114438195A (en) | Alzheimer's disease detection kit, storage medium and electronic device | |
CN108949954A (en) | The application of kit and ALOX15 gene as biomarker for detecting chronic nasosinusitis with nasal polyp hypotype | |
CN115305283A (en) | Exosome small non-coding RNA molecular marker and application thereof | |
CN106191032B (en) | The Disease-causing gene model and its construction method of dysnoesia disease and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181130 |